Inflammation & repair
Macrophages and other immune cells exchange signals with surrounding tissue. Cytokines, growth factors, and ovarian hormones can interact in the local environment.
THE RESEARCH ROOM
The reasoning behind the formula, made tangible: biological pathways, ingredient mechanisms, and direct links to the studies.
START WITH THE CONDITION
Endometriosis involves endometrial-like tissue outside the uterus. Adenomyosis involves endometrial glands and stroma within the uterine muscle. They can coexist, but they are distinct conditions.
Macrophages and other immune cells exchange signals with surrounding tissue. Cytokines, growth factors, and ovarian hormones can interact in the local environment.
The textbook describes altered estrogen-receptor patterns and reduced progesterone responsiveness in endometriosis. That is more complex than a single “high estrogen” explanation.
Repeated tissue injury and repair, platelets, and remodeling processes are part of the research picture. Mature scar tissue is not simply a blood clot.
Background: Oral, ed. · Endometriosis and Adenomyosis: Global Perspectives Across the Lifespan · Springer, 2022 ↗. Chapters 4, 5, 7 and 31. This textbook provides condition biology; it does not evaluate or endorse ENDOLLS.
THE FORMULATION RATIONALE
The ENDOLLS manuscript follows several biological themes rather than a single target. Explore each theme through the ingredients and papers behind it.
Rhodiola, white willow, and rose hip
Explore the mechanisms →02DIM in Renewal
Explore the mechanism →03Valerian in both formulas
Explore the mechanism →04Nattokinase in both formulas
Explore the mechanism →05Oat beta-glucan in both formulas
Explore the mechanism →This is ENDOLLS’s rationale for investigating a combination. Shared pathway names across separate experiments do not establish that the ingredients act together as proposed, or that the finished regimen treats endometriosis or adenomyosis.
OPEN THE PAPER, NOT JUST THE PROMISE
Selected references from the manuscript, plus directly relevant primary studies.
Showing all 30 studies
Pancreatic cancer cells and a mouse tumor model
Lower HIF-1α/LOXL2 signaling and changes in invasion-related markers.
Different tissue, disease, and exposure from oral Advanced Duo.
Rat lung-injury model; supporting cell experiments
Changes in antioxidant signaling, inflammatory activity, and fibrosis markers.
A lung model does not demonstrate removal of pelvic adhesions.
Isolated human uterine muscle in tissue baths
Extracts reduced contraction in a concentration-dependent manner.
Human tissue outside the body is not a clinical trial.
Randomized, placebo-controlled trial · 100 students
Studied menstrual pain using 255 mg three times daily for three days per cycle, across two cycles.
Different preparation and schedule; primary dysmenorrhea is not endometriosis.
Cultured retinal endothelial cells
Reduced IL-1β-driven inflammatory signals and NF-κB activation.
An eye-cell experiment does not establish pain relief from the Duo.
Engineered and cancer-derived cell systems
ERβ-linked gene activation involving the SRC-2 coactivator.
Receptor activity varies by cell context; this is not evidence of hormone balance in patients.
Breast cancer cells without estradiol
Low DIM concentrations activated ERα and promoted proliferation in this setting.
Shows why a molecule cannot be labeled universally anti-estrogenic.
Immune-cell and cartilage-cell systems
Rose hip preparations changed inflammatory mediators and tissue-remodeling enzymes.
The tested powder and galactolipid differ from a 20% polyphenol extract.
Double-blind crossover study · 12 healthy young men
A single 2,000 FU dose changed several blood clotting/breakdown markers within normal ranges.
Did not study pelvic adhesions, endometriosis, adenomyosis, or long-term outcomes.
Randomized dietary study · 48 people with chronic gastritis · 30 days
The high-molar-mass preparation showed favorable mucosal and biochemical changes.
Different preparation and exposure; does not validate the Duo’s 90 mg-per-capsule amount.
Human bladder cancer cell lines
Explores how rhodiola extract and salidroside affect growth signaling and cellular recycling.
Cancer-cell experiments do not demonstrate an endometriosis treatment effect.
Isolated animal smooth muscle and rat experiments
Investigates potassium-channel activity as an explanation for smooth-muscle relaxation.
Uses Valeriana wallichii, a different species and preparation from the labeled valerian extract.
Randomized, double-blind crossover trial in hemodialysis patients
Examines sleep quality, depression and state anxiety with a valerian preparation.
A dialysis population and a different preparation; does not establish outcomes with Advanced Duo.
Human breast epithelial cell lines
Compares DIM, indole-3-carbinol and cabbage preparations on CYP19, the gene encoding aromatase.
Responses varied by cell type. These findings do not mean DIM uniformly lowers estrogen in people.
Cell-based experiments and mouse liver experiments
Studies antioxidant and phase II enzyme gene responses to dietary indoles, including DIM.
Different exposures and combinations; changes in gene activity are not clinical outcomes.
Double-blind, randomized placebo-controlled osteoarthritis trial
Examines joint pain and mobility with a standardized Rosa canina preparation.
Osteoarthritis differs from endometriosis, and the tested powder is not the Duo’s polyphenol extract.
In vitro model of choroidal neovascularization
Examines HIF-1 activity in an eye-related blood-vessel growth model.
A laboratory eye model cannot establish effects on pelvic lesions or oral supplement efficacy.
Isolated human neuroglia cell line
Investigates neuropeptide Y and Hsp72 responses to salidroside and the ADAPT-232 herbal combination.
ADAPT-232 is a different formula; cultured cells are not a trial of stress or fatigue in patients.
Rat cerebral ischemia/reperfusion model
Explores dopamine-related changes and behavior following an experimental brain injury.
The injury model, administration and doses differ from an oral daily regimen.
Drug-resistant prostate cancer cell line
Investigates growth and Wnt/β-catenin signaling in cells exposed to DIM.
Prostate cancer biology is not interchangeable with endometriosis biology.
Prostate and other cell-line experiments
Tests the relationship between DIM, p38 signaling and p75NTR-dependent cell death.
A cancer-cell mechanism does not prove that DIM selectively removes endometriotic lesions.
Human liver cancer cell lines
Examines calcium signaling and p38 MAPK in experiments with DIM and a calcium ionophore.
The experimental combination is not Advanced Duo; this is not a recommendation to combine supplements.
Human retinal pigment epithelial cells under chemical hypoxia
Studies VEGF expression and the HIF-1α and NF-κB pathways.
Results in eye cells do not demonstrate suppression of endometriosis-related blood-vessel growth.
Mouse immune-cell cultures and animal experiments
Examines immune-cell proliferation, cytokines and responses to an intestinal virus.
Immune stimulation is context dependent; it is not evidence that more activation is always beneficial.
Peripheral blood leukocytes and cartilage-related cell models
Compares rose hip preparations and their effects on inflammatory mediators.
Different preparations produced different responses; they are not equivalent to the labeled Duo extract.
Mouse oxygen-induced retinopathy and endothelial cell experiments
Studies retinal vessel growth, glial activation and Nrf2/HO-1 signaling.
Retinal research does not establish an effect on pelvic adhesions or endometriotic lesions.
Mouse gastric-injury model and cultured cells
Investigates gastric protection, HSP70 and mucin using a branched fungal beta-glucan.
Fungal (1,3)/(1,6) beta-glucan differs structurally from the Duo’s oat (1,3)/(1,4) beta-glucan.
Human monocyte/macrophage experiments, including ex vivo samples
Examines epigenetic responses to beta-glucan after LPS-induced immune tolerance.
This is not a clinical trial of oral oat beta-glucan. Structure, route and exposure matter.
Experimental renal-injury and cell models
Studies inflammation-related pathways, including ADAM17 and neutral sphingomyelinase 2.
Uses barley-derived material and renal models, not the Duo’s oat extract in endometriosis.
Rat aspirin-induced gastric-injury model
Examines gastric tissue and biochemical markers after beta-glucan pretreatment.
Aspirin-injury pretreatment in rats does not establish gastrointestinal benefits at the Duo’s dose.
A “human study” may concern another condition or only measure a biomarker. It is not automatically evidence of an endometriosis benefit. Doses listed here describe research, not product instructions.
SCIENCE, TRANSLATED
KEEP THE LEVELS OF EVIDENCE SEPARATE
The textbook describes condition biology. The manuscript explains the founder’s formulation reasoning and points to published research. The linked papers show what each experiment actually tested.
These materials do not provide a published randomized controlled trial of the exact Advanced Duo formulation. They do not establish lesion removal, a guaranteed response, or a proven increase in efficacy from adding Ruby Radiance.
Current formulation: Product amounts on this site follow the current label, not historical manuscript specifications. Resveratrol is not listed as an Advanced Duo ingredient.